National Academies Press: OpenBook

Ovarian Cancers: Evolving Paradigms in Research and Care (2016)

Chapter: Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer

« Previous: Appendix B: Glossary
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×

Appendix C

Open and Active Clinical Trials on Epithelial Ovarian Cancer1

This appendix includes a listing of the clinical trials in epithelial ovarian cancer that are open and recruiting, open and not yet recruiting (denoted by an asterisk), or active but closed to recruiting as of the writing of this report. The data in this table were generated by a search performed on www.ClinicalTrials.gov on December 4, 2015, using the subtopic of “epithelial ovarian cancer.” Studies with an “unknown” status have been excluded. This search resulted in 204 interventional studies and 31 observational studies. The studies are presented in the following table by study phase and by study type (interventional versus observational). The table lists the types of interventions used in each study, but does not include placebos (where used), nor the different types of administration of the same intervention (e.g., different dosage amounts of the same drug).

The purpose of this appendix is to give a broader sense of the types of studies that are under way as well as to give a sense of the priority areas of focus. This appendix is not intended to serve as an exhaustive list of all studies currently under way in ovarian cancer. The committee also acknowledges that many of these studies are not limited to ovarian cancers. Furthermore, the committee acknowledges that by limiting the list to studies that specifically target epithelial ovarian cancers, the many more studies being performed on ovarian cancers in general are excluded. A similar search done under the subtopic of ovarian cancer in general revealed 385 open studies and 223 studies that are closed and active but not recruiting. These numbers likely include the studies listed in this appendix.

________________

1 Open trials listed on www.ClinicalTrials.gov as of December 4, 2015.

Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
NCT Number Title Drug Intervention
Phase I Interventional Studies
NCT01536054 Sirolimus and Vaccine Therapy in Treating Patients With Stage II–IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Sirolimus
NCT01155258 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Temsirolimus; vinorelbine ditartrate
NCT00357448 Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer N/A
NCT01074411 Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Bortezomib; carboplatin
NCT01322802 Vaccine Therapy in Treating Patients With Stage III–IV or Recurrent Ovarian Cancer N/A
NCT00436254 Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With HER-2 Positive Stage III–IV Breast Cancer or Ovarian Cancer N/A
NCT02046421 Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Mifepristone; carboplatin; gemcitabine hydrochloride
NCT00602277 Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy N/A
NCT01715168 A Crossover Bioequivalence Study of Intravenously Administered ATI-0918 and DOXIL/CAELYX in Patients With Ovarian Cancer DOXIL/CAELYX; ATI-0918
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Biological Intervention Other Intervention Estimated Enrollment Sponsor/Collaborators
ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine; sargramostim Laboratory biomarker analysis (LBA) 7 Roswell Park Cancer Institute; National Cancer Institute (NCI); Sanofi Pasteur, a Sanofi Company
N/A N/A 19 University of Southern California; Wyeth (now a wholly owned subsidiary of Pfizer)
Denileukin diftitox LBA; intraperitoneal (IP) administration; enzyme-linked immunosorbent assay; flow cytometry 11 University of Washington; NCI
N/A LBA; pharmacological study 36 NCI
pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine LBA 22 University of Washington; NCI
pNGVL3-hICD vaccine; sargramostim Flow cytometry; immunologic technique; immunoenzyme technique; protein expression analysis; biopsy 66 University of Washington; NCI
N/A LBA; pharmacological study 22 University of Chicago; NCI
Wild-type reovirus LBA 14 NCI
N/A N/A 40 Azaya Therapeutics, Inc.
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
NCT Number Title Drug Intervention
NCT01940172 Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer Birinapant; conatumumab
NCT01459380 Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Carboplatin; pegylated liposomal doxorubicin hydrochloride; veliparib
NCT02270372 Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer N/A
NCT00562640 Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009) Cyclophosphamide
NCT00408590 Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer, or Primary Peritoneal Cancer N/A
NCT02159716 CART-meso in Mesothelin Expressing Cancers N/A
NCT01649336 A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer MEK162, MEK inhibitor (oral); paclitaxel, mitotic inhibitor (intravenous)
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Biological Intervention Other Intervention Estimated Enrollment Sponsor/Collaborators
N/A N/A 40 TetraLogic Pharmaceuticals
Bevacizumab LBA 48 NCI
ONT-10, varlilumab combination N/A 42 Oncothyreon, Inc.; Celldex Therapeutics
Filgrastim; therapeutic autologous lymphocytes LBA 21 Memorial Sloan Kettering Cancer Center; NCI
Carcinoembryonic antigen-expressing measles virus; oncolytic measles virus encoding thyroidal sodium iodide symporter reaction LBA; reverse transcriptase-polymerase chain 46 Mayo Clinic; NCI
CART-meso N/A 21 Abramson Cancer Center of the University of Pennsylvania
N/A N/A 36 Array BioPharma
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
NCT Number Title Drug Intervention
NCT01121640 A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women N/A
NCT01286987 Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors BMN 673
NCT01606241 Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II–III Breast or Stage II–IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Cyclophosphamide
NCT01522820 Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Sirolimus
NCT01264432 Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer Veliparib
NCT00892736 Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy Veliparib
NCT00410553 Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery Eribulin mesylate; gemcitabine hydrochloride
NCT01220154 Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer Bevacizumab; paclitaxel; carboplatin
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Biological Intervention Other Intervention Estimated Enrollment Sponsor/Collaborators
N/A CA-125 assay on Abbott Architect i1000SR platform; HE4 assay on Architect i1000SR platform; transvaginal ultrasound 1,208 Fred Hutchinson Cancer Research Center; The Marsha Rivkin Center for Ovarian Cancer Research; Canary Foundation; Swedish Medical Center; Beckman Research Institute; Cedars-Sinai Medical Center; Stanford University; Fox Chase Cancer Center
N/A N/A 113 BioMarin Pharmaceutical
Multi-epitope folate receptor alpha peptide vaccine LBA 24 Mayo Clinic; NCI
DEC-205/NY-ESO-1 fusion protein CDX-1401 LBA; pharmacological study 30 Roswell Park Cancer Institute; NCI
N/A LBA; quality-of-life (QOL) assessment; radiation therapy 40 NCI
N/A LBA; pharmacological study 120 NCI
N/A N/A 45 NCI
N/A N/A 9 David O’Malley; Genentech, Inc.; Ohio State University Comprehensive Cancer Center
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
NCT Number Title Drug Intervention
NCT01314105 BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma, or Primary Peritoneal Cancer BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
NCT00825201 Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity Paclitaxel albumin-stabilized nanoparticle formulation
NCT00652691 Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer Carboplatin; cyclophosphamide; topotecan hydrochloride
NCT01445418 AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer AZ2281 + carboplatin
NCT02083536* LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma Docetaxel
NCT02275039* p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer Gemcitabine hydrochloride
NCT01489371* EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Pegylated liposomal doxorubicin hydrochloride
NCT01249443* Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection Vorinostat; carboplatin; paclitaxel
NCT02606305* Study of IMGN853 in Comb. With Bevacizumab, Carboplatin, or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer IMGN853; bevacizumab; carboplatin; doxorubicin
NCT02260544* Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection Doxorubicin hydrochloride liposome injection
NCT02014337* Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Mifepristone and eribulin in combination
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Biological Intervention Other Intervention Estimated Enrollment Sponsor/Collaborators
N/A N/A 19 Boehringer Ingelheim
N/A Liquid chromatography; mass spectrometry; pharmacological study; LBA 29 City of Hope Medical Center; NCI; National Comprehensive Cancer Network
Filgrastim Autologous hematopoietic stem cell transplantation; peripheral blood stem cell transplantation 48 Mayo Clinic; NCI
N/A N/A 103 NCI; National Institutes of Health Clinical Center (CC)
N/A Low-dose fractionated whole abdominal radiation therapy 12 University of Miami
Modified vaccinia virus ankara vaccine expressing p53 LBA 9 City of Hope Medical Center; NCI
EGEN-001 LBA 18 Gynecologic Oncology Group; NCI
N/A Diagnostic LBA; pharmacological study 26 AIDS Malignancy Consortium; NCI; The EMMES Corporation
N/A N/A 145 ImmunoGen, Inc.
N/A N/A 48 Dr. Reddy’s Laboratories Limited
N/A N/A 40 Corcept Therapeutics
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
NCT Number Title Drug Intervention
NCT02083536* LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma Docetaxel
NCT02275039* p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer Gemcitabine hydrochloride
NCT01489371* EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Pegylated liposomal doxorubicin hydrochloride
NCT01249443* Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection Vorinostat; carboplatin; paclitaxel
NCT02606305* Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer IMGN853; bevacizumab; carboplatin; doxorubicin
NCT02260544* Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection Doxorubicin hydrochloride liposome injection
NCT02014337* Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Mifepristone and eribulin in combination
NCT02520115* Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples from Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer Dexamethasone; valproic acid
NCT01281514* Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Everolimus; carboplatin; pegylated liposomal doxorubicin hydrochloride
NCT02480374* Study of Safety & Biological Activity of IP GEN-1 With Neoadjuvant Chemo in Ovarian Cancer N/A
NCT02324439* Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission N/A
NCT02312661* Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer Metformin; paclitaxel; carboplatin
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Biological Intervention Other Intervention Estimated Enrollment Sponsor/Collaborators
N/A Low-dose fractionated whole abdominal radiation therapy 12 University of Miami
Modified vaccinia virus ankara vaccine expressing p53 LBA 9 City of Hope Medical Center; NCI
EGEN-001 LBA 18 Gynecologic Oncology Group; NCI
N/A Diagnostic LBA; pharmacological study 26 AIDS Malignancy Consortium; NCI; The EMMES Corporation
N/A N/A 145 ImmunoGen, Inc.
N/A N/A 48 Dr. Reddy’s Laboratories Limited
N/A N/A 40 Corcept Therapeutics
N/A LBA 180 Barbara Ann Karmanos Cancer Institute; NCI
N/A 24 Fox Chase Cancer Center
GEN-1 N/A 15 Celsion
N/A Omega Nutrition cold-milled flaxseeds 90 Southern Illinois University
N/A N/A 20 University Medical Center Groningen
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
NCT Number Title Drug Intervention
NCT02534922* Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer N/A
NCT02470559* Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Is Stage III–IV, Refractory, or Recurrent N/A
NCT02432963* Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy N/A
NCT02298959* Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors N/A
NCT02142803* TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors TORC1/2 inhibitor INK128
NCT01145430* Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer Pegylated liposomal doxorubicin hydrochloride; veliparib
NCT02344095* A Trial of Weekly Paclitaxel With Oncothermia and Weekly Cisplatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer Weekly paclitaxel; weekly cisplatin
NCT00989651* Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II–IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Carboplatin; cisplatin; paclitaxel; veliparib
NCT02199171* Heated Carboplatin in Treating Patients With Stage II–IV Ovarian, Fallopian Tube, or Peritoneal Cancer Carboplatin
NCT01665183* Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma ADI-PEG 20
NCT02000778* EC17 for Intraoperative Imaging in Occult Ovarian Cancer EC17
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Biological Intervention Other Intervention Estimated Enrollment Sponsor/Collaborators
Prolanta, a human prolactin receptor antagonist N/A 18 Oncolix, Inc.
Aldesleukin; HER2Biarmed activated T cells; sargramostim LBA 20 Barbara Ann Karmanos Cancer Institute; NCI
Modified vaccinia virus ankara vaccine expressing p53; pembrolizumab LBA 12 City of Hope Medical Center; NCI
Pembrolizumab; ziv-aflibercept LBA 36 NCI
Bevacizumab LBA; pharmacological study 60 NCI
N/A LBA; pharmacological study 58 NCI
N/A Oncothermia 12 Seoul National University Hospital
Bevacizumab LBA 474 NCI
N/A N/A 30 University of California, Irvine
N/A N/A 89 Polaris Group
N/A N/A 10 University of Pennsylvania
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
NCT Number Title Drug Intervention
NCT02530047* Mesenchymal Stem Cells (MSC) for Ovarian Cancer N/A
NCT02303912* Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer Nuc-1031; carboplatin
NCT02534922* Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer N/A
NCT02627430* Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer HSP90 inhibitor AT13387; talazoparib
NCT02530047* Mesenchymal Stem Cells (MSC) for Ovarian Cancer N/A
Phase I/II Interventional Studies
NCT00553683 Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer Cyclophosphamide; poly ICLC
NCT01472783 Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation Veliparib
NCT01091428 MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer MLN8237 + paclitaxel
NCT01238770 Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-Resistant Recurrent Ovarian Cancer Pazopanib
NCT00317772 Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer Topotecan; gefitinib
NCT02244502* Safety, Feasibility, and Effect of TTFields Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma Paclitaxel
NCT01709487* Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First-Line Therapy N/A
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Biological Intervention Other Intervention Estimated Enrollment Sponsor/Collaborators
N/A MSC-INFβ; questionnaires 21 MD Anderson Cancer Center
N/A N/A 36 Imperial College Healthcare NHS Trust
Prolanta, a human prolactin receptor antagonist N/A 18 Oncolix, Inc.
N/A LBA; pharmacological study 40 NCI
MSC-INFβ Questionnaires 21 MD Anderson Cancer Center
N/A Hepatic artery embolization; 3-dimensional conformal radiation therapy 50 Rutgers, The State University of New Jersey
N/A N/A 49 Vejle Hospital; Abbott
N/A N/A 172 Millennium Pharmaceuticals, Inc.
N/A N/A 57 Priv.-Doz. Dr. med. Joachim Rom; University Hospital Heidelberg
N/A N/A 52 MD Anderson Cancer Center; AstraZeneca; GlaxoSmithKline
N/A NovoTTF-100L(O) (device) 30 NovoCure, Ltd.
N/A Hyperthermic intraperitoneal chemotherapy (HIPEC) 24 Jules Bordet Institute
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
NCT Number Title Drug Intervention
NCT01631552* Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers IMMU-132
NCT01962948* Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Paclitaxel; ganetespib
NCT02068794* MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer N/A
NCT01402271* Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer Carboplatin; paclitaxel; pazopanib hydrochloride
NCT02584478* A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818 to Standard Platinum-Based Chemotherapy AL3818; carboplatin; paclitaxel
NCT02335918* A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors Combination of varlilumab and nivolumab
NCT02166905* DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission Poly ICLC; IDO1 inhibitor INCB024360
NCT02012192* GANNET53: Ganetespib in Metastatic, p53Mutant, Platinum-Resistant Ovarian Cancer Ganetespib; paclitaxel
NCT01663857* A Study of LY2228820 for Recurrent Ovarian Cancer LY2228820; carboplatin; gemcitabine
NCT01116648* Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Cediranib maleate; olaparib
NCT02028117* Phase I/II Study of Enadenotucirev Intraperitoneally in Ovarian Cancer Patients N/A
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Biological Intervention Other Intervention Estimated Enrollment Sponsor/Collaborators
N/A N/A 250 Immunomedics, Inc.
N/A LBA 74 Fox Chase Cancer Center; NCI
Oncolytic measles virus encoding thyroidal sodium iodide symporter LBA; mesenchymal stem cell transplantation 54 Mayo Clinic; NCI
N/A LBA; pharmacological study 96 European Organisation for Research and Treatment of Cancer (EORTC)
N/A N/A 48 Advenchen Laboratories, LLC
N/A N/A 190 Celldex Therapeutics; Bristol-Myers Squibb
DEC-205/NY-ESO-1 fusion protein CDX-1401 LBA; pharmacological study 98 Roswell Park Cancer Institute; NCI; Celldex Therapeutics
N/A N/A 222 Medical University Innsbruck; European Commission
N/A N/A 116 Eli Lilly and Company
N/A LBA; pharmacological study 162 NCI
Enadenotucirev N/A 35 PsiOxus Therapeutics, Ltd
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
NCT Number Title Drug Intervention
NCT02354131* Niraparib and/or Niraparib-Bevacizumab Combination Against Bevacizumab Alone in HRD Platinum-Sensitive Ovarian Cancer Niraparib; bevacizumab
NCT02098343* p53 Suppressor Activation in Recurrent High-Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 APR-246; carboplatin; pegylated liposomal doxorubicin hydrochloride
Phase II Interventional Studies
NCT02107950 Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma Standard of care chemotherapy
NCT01039207 Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer N/A
NCT02107378 Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma Standard of care (paclitaxel or topotecan or doxorubicin)
NCT01118052 EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer N/A
NCT00679783 Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High-Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/Triple Neg Breast Cancer AZD2281
NCT00993655 Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Carboplatin; cisplatin; paclitaxel
NCT00979992 Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer Sunitinib malate
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Biological Intervention Other Intervention Estimated Enrollment Sponsor/Collaborators
N/A N/A 147 Nordic Society for Gynaecologic Oncology; ENGOT; GCIG; Stanford University
N/A N/A Null Aprea AB
 
DCVAC/OvCa N/A 60 Sotio a.s.
Rilotumumab Diagnostic LBA 50 Gynecologic Oncology Group; NCI
DCVAC/OvCa N/A 60 Sotio a.s.
EGEN-001 LBA 56 Gynecologic Oncology Group; NCI
N/A N/A 112 AstraZeneca; British Columbia Cancer Agency
N/A QOL assessment 275 NCIC Clinical Trials Group; NCI; Grupo Español de Investigación en Cáncer de Ovario; Cancer Research UK; Southwest Oncology Group
N/A LBA 53 NCI
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
NCT Number Title Drug Intervention
NCT00538031 Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Cyclophosphamide; celecoxib
NCT00278343 Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer Cediranib maleate
NCT02283658 Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Everolimus; letrozole
NCT01666444 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Pegylated liposomal doxorubicin (PLD); VTX-2337
NCT00511992 Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer Avastin
NCT00872989 S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Docetaxel; vandetanib
NCT01097746 First-line Treatment of Weekly Paclitaxel With Carboplatin and Bevacizumab in Ovarian Cancer Carboplatin; paclitaxel; bevacizumab
NCT01720173 Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer N/A
NCT01716715 Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Cabozantinib S-malate; paclitaxel
NCT01540565 Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Veliparib
NCT01468909 Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Paclitaxel; pazopanib hydrochloride
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Biological Intervention Other Intervention Estimated Enrollment Sponsor/Collaborators
N/A N/A 27 City of Hope Medical Center
N/A LBA 74 NCI
N/A LBA 20 Mayo Clinic; NCI
N/A N/A 290 VentiRx Pharmaceuticals Inc.; Gynecologic Oncology Group
N/A N/A 22 University of Oklahoma; Genentech, Inc.
N/A N/A 120 Southwest Oncology Group; NCI
N/A N/A 30 MD Anderson Cancer Center; Genentech, Inc.
Dalantercept LBA 56 Gynecologic Oncology Group; NCI
N/A LBA 102 NCI
N/A LBA 51 NCI
N/A LBA 110 NCI
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
NCT Number Title Drug Intervention
NCT01305213 Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Fosbretabulin tromethamine
NCT01199263 Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Paclitaxel
NCT01010126 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Temsirolimus
NCT02324595 Minimally Invasive Interval Debulking Surgery in Ovarian Neoplasm: A Feasibility Study N/A
NCT01991210 A Randomized Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer DNIB0600A; pegylated liposomal doxorubicin
NCT00857545 OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission N/A
NCT00744718 Bevacizumab and Carboplatin for Patients With Ovarian Cancer Bevacizumab; carboplatin
NCT00551070 Selumetinib in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer Selumetinib
NCT01460979 Activity, Tolerability, Safety of Temsirolimus in Women With Ovarian Cancer Who Progressed During Previous Platinum Chemotherapy or Within 6 Months After Therapy or Advanced Endometrial Carcinoma Temsirolimus
NCT00373217 Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Carboplatin; paclitaxel
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Biological Intervention Other Intervention Estimated Enrollment Sponsor/Collaborators
Bevacizumab LBA 110 NCI
Wild-type reovirus LBA 110 NCI
Bevacizumab N/A 299 NCI
N/A Laparoscopic interval debulking surgery 30 Catholic University of the Sacred Heart; Fagotti, Anna, M.D.; Francesco Fanfani; Salvatore Gueli Alletti
N/A N/A 95 Genentech, Inc.
Immunoadjuvant OPT-821; polyvalent antigen-KLH conjugate vaccine LBA 164 Gynecologic Oncology Group; NCI
N/A N/A 30 Vejle Hospital
N/A LBA; pharmacological study 52 NCI
N/A N/A 86 AGO Study Group
MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine; tetanus toxoid helper peptide Conventional surgery 28 Craig L Slingluff, Jr.; NCI; University of Virginia
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
NCT Number Title Drug Intervention
NCT01551745 Salvage Ovarian FANG™ Vaccine + Bevacizumab Bevacizumab
NCT01439659 Juice Plus+ and Juice Plus+ Complete in Ovarian Cancer N/A
NCT01309230 Trial of Adjuvant FANG™ Vaccine for High-Risk Stage III/IV Ovarian Cancer N/A
NCT02435186* p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer p53 gene; cisplatin; paclitaxel
NCT02107937* Phase II Study DCVAC/OvCa Added to First-Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma Standard of care
NCT01764802* Psychosexual Intervention in Patients With Stage I–III Gynecologic or Breast Cancer N/A
NCT02122185* Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III–IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Paclitaxel; carboplatin; docetaxel; metformin hydrochloride
NCT00888615* Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Elesclomol sodium; paclitaxel
NCT02584465* REGorafenib vs. Tamoxifen in Patients With Platinum-Sensitive Ovarian Carcinoma and Isolated Biological Progression Tamoxifen; regorafenib
NCT02487849* HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-Sensitive Recurrence of Ovarian Carcinoma Carboplatin
NCT01899599* PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer PankoMab-GEX
NCT02033616* Autologous Dendritic Cell-Tumor Cell Immunotherapy for Advanced Epithelial Ovarian Carcinomas N/A
NCT02487693* Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for Patients With Ovarian Carcinoma N/A
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Biological Intervention Other Intervention Estimated Enrollment Sponsor/Collaborators
Vigil™ vaccine N/A 5 Gradalis, Inc.
N/A Nutritional counseling; daily supplements 75 MD Anderson Cancer Center; Natural Alternatives International
Vigil™ N/A 44 Gradalis, Inc.
N/A N/A 100 Shenzhen SiBiono; GeneTech Co., Ltd.
DCVAC/OvCa N/A 90 Sotio a.s.
N/A Behavioral, psychological, or informational intervention 100 Ohio State University Comprehensive Cancer Center; NCI
N/A LBA 160 University of Chicago; NCI
N/A N/A 55 Gynecologic Oncology Group; NCI
N/A N/A 116 ARCAGY/GINECO GROUP; Bayer
N/A HIPEC 10 Krankenhaus Barmherzige Schwestern Linz
N/A N/A 210 Glycotope GmbH
Ovapuldencel-T; MC: autologous PBMCs in GM-CSF N/A 99 Caladrius Biosciences, Inc.
Cytokine-induced killer cells Radiofrequency ablation 50 The First People’s Hospital of Changzhou
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
NCT Number Title Drug Intervention
NCT02437812* Study of Paclitaxel, Carboplatin, and Oral Metformin in the Treatment of Advanced-Stage Ovarian Carcinoma Metformin; paclitaxel; carboplatin
NCT01735071* Bevacizumab and Trabectedin +/–Carboplatin in Advanced Ovarian Cancer Bevacizumab; trabectedin; carboplatin
NCT02315430* Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Cabozantinib S-malate
NCT02569957* Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High-Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Topotecan hydrochloride; acetylcysteine
NCT02124421* Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Adjuvant chemotherapy; carboplatin; paclitaxel; cisplatin
NCT02364713* MV-NIS or Investigator’s Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Pegylated liposomal doxorubicin hydrochloride; gemcitabine hydrochloride; topotecan hydrochloride; paclitaxel
NCT02101775* Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Gemcitabine hydrochloride; WEE1 inhibitor AZD1775
NCT02125513* Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer Carboplatin; paclitaxel
NCT02025985* Phase II Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies & Metastatic Breast Cancer Selinexor
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Biological Intervention Other Intervention Estimated Enrollment Sponsor/Collaborators
N/A N/A 30 Gynecologic Oncology Associates; University of North Carolina at Chapel Hill
N/A N/A 74 Mario Negri Institute for Pharmacological Research; PharmaMar; Hoffmann-La Roche
N/A LBA 34 NCI
N/A N/A 48 Thomas Jefferson University; NIH
N/A Cytoreductive surgery; questionnaire; HIPEC 48 Mercy Medical Center
Oncolytic measles virus encoding thyroidal sodium iodide symporter LBA; QOL assessment 134 Mayo Clinic; NCI
N/A LBA; pharmacological study 100 NCI
N/A Surgery 220 Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi
N/A N/A 105 Karyopharm Therapeutics, Inc.
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
NCT Number Title Drug Intervention
NCT01936974* (PGA) for Platinum-Resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma Gemcitabine; bevacizumab; carboplatin; cisplatin; oxaliplatin
NCT02595021* Total/Subtotal Colectomy in Ovarian Cancer N/A
NCT01891344* A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) Oral rucaparib
NCT01536743* A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression PD0332991
NCT02595892* Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer ATR kinase inhibitor VX-970; gemcitabine hydrochloride
NCT02345265* Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer Cediranib maleate; olaparib
NCT02312245* Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Gemcitabine hydrochloride; paclitaxel; pegylated liposomal doxorubicin hydrochloride; topotecan hydrochloride
NCT02059265* Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial, or Peritoneal Cancer Dasatinib
NCT01853644* Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Tivozanib
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Biological Intervention Other Intervention Estimated Enrollment Sponsor/Collaborators
N/A N/A 88 Western Regional Medical Center
N/A Total or subtotal colectomy; other bowel resection 80 Shanghai Gynecologic Oncology Group; Shanghai Zhongshan Hospital
N/A N/A 480 Clovis Oncology, Inc.; Foundation Medicine
N/A N/A 30 Jonsson Comprehensive Cancer Center
N/A LBA 70 NCI
N/A LBA; pharmacological study 70 NCI
N/A N/A 60 Mayo Clinic; NCI
N/A LBA 62 NCI
N/A N/A 30 Northwestern University; National Comprehensive Cancer Network
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
NCT Number Title Drug Intervention
NCT01669226* First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer PEip (weekly) and TCiv; TCiv
NCT01669798* BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer BIBF 1120
NCT02135523* The Efficacy of Involved-field Radiation Therapy for Residual or Locoregionally Recurrent Epithelial Ovarian Cancer After Definitive Treatment; Multi-institutional Clinical Trial N/A
NCT02435186* p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer p53 gene; cisplatin; paclitaxel
NCT02487849* HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-Sensitive Recurrence of Ovarian Carcinoma Carboplatin
NCT02033616* Autologous Dendritic Cell-Tumor Cell Immunotherapy for Advanced Epithelial Ovarian Carcinomas N/A
NCT02631876* PH2 Study of IMGN853 vs. Investigator’s Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal, or Primary Fallopian Tube Cancer IMGN853; paclitaxel; doxorubicin; gemcitabine; topotecan
NCT02487693* Radiofrquency Ablation Combined With Cytokine-Induced Killer Cells for the Patients With Ovarian Carcinoma N/A
NCT02627443* Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer ATR kinase inhibitor VX-970; carboplatin; gemcitabine hydrochloride
NCT02595892* Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer ATR kinase inhibitor VX-970; gemcitabine hydrochloride
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Biological Intervention Other Intervention Estimated Enrollment Sponsor/Collaborators
N/A N/A 200 Shanghai Gynecologic Oncology Group; Fudan University; Shanghai Jiao Tong University School of Medicine; Shanghai Zhongshan Hospital
N/A N/A 56 AA Secord; Boehringer Ingelheim; Duke University
N/A Involved-field radiation therapy 70 Yonsei University
N/A N/A 100 Shenzhen SiBiono GeneTech Co., Ltd.
N/A HIPEC 10 Krankenhaus Barmherzige Schwestern Linz
Ovapuldencel-T; MC: autologous PBMCs in GM-CSF N/A 99 Caladrius Biosciences, Inc.
N/A N/A 247 ImmunoGen, Inc.
Cytokine-induced killer cells Radiofrequency ablation 50 The First People’s Hospital of Changzhou
N/A LBA; pharmacological study 117 NCI
N/A LBA 70 NCI
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
NCT Number Title Drug Intervention
Phase II/III Interventional Studies
NCT02101788* Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Letrozole; paclitaxel; pegylated liposomal doxorubicin hydrochloride; tamoxifen citrate; topotecan hydrochloride; trametinib
NCT02502266* Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Cediranib maleate; olaparib; paclitaxel; pegylated liposomal doxorubicin hydrochloride; topotecan hydrochloride
NCT01506856* Intraperitoneal Therapy for Ovarian Cancer With Carboplatin Trial IV paclitaxel + IV carboplatin; IV paclitaxel + IP carboplatin
Phase III Interventional Studies
NCT00951496 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II–III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Carboplatin; cisplatin; paclitaxel
NCT01167712 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Carboplatin; paclitaxel
NCT01081262 Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II–IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Capecitabine; carboplatin; oxaliplatin; paclitaxel
NCT00954174 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Paclitaxel; carboplatin; ifosfamide
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Biological Intervention Other Intervention Estimated Enrollment Sponsor/Collaborators
N/A LBA; pharmacological study; QOL assessment 250 NCI
N/A LBA; questionnaire administration 680 NCI
N/A N/A 654 Gynecologic Oncology Trial & Investigation Consortium; Japanese Gynecologic Oncology Group
Bevacizumab LBA; QOL assessment 1500 NCI
Bevacizumab Computed tomography; therapeutic conventional surgery 650 NCI
Bevacizumab LBA; QOL assessment 332 NCI
N/A QOL assessment 603 Gynecologic Oncology Group; NCI
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
NCT Number Title Drug Intervention
NCT00108745 Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer Paclitaxel poliglumex; paclitaxel
NCT00305851 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant N/A
NCT01684878 A Study of Pertuzumab in Combination With Standard Chemotherapy in Women With Recurrent Platinum-Resistant Epithelian Ovarian Cancer and Low HER3 mRNA Expression Chemotherapy; pertuzumab
NCT01376349 Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms Prasterone
NCT01837251 Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Carboplatin; PLD
NCT01462890 Evaluation of Optimal Initial Treatment Duration of Bevacizumab in Combination With Standard Chemotherapy in Patients With Ovarian Cancer Paclitaxel; carboplatin
NCT01281254 AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) AMG386; PLD
NCT00719303* Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer N/A
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Biological Intervention Other Intervention Estimated Enrollment Sponsor/Collaborators
N/A Clinical observation 1,100 Gynecologic Oncology Group; NCI
N/A Music therapy (books on tape); psychosocial assessment and care; QOL assessment; music video 118 Children’s Oncology Group; NCI; National Institute of Nursing Research (NINR)
N/A N/A 208 Hoffmann-La Roche
N/A N/A 464 Alliance for Clinical Trials in Oncology; NCI; Mayo Clinic
Bevacizumab N/A 682 AGO Research GmbH; Arbeitsgemeinschaft Gynaekologische Onkologie Austria; ARCAGY/GINECO GROUP; ANZGOG; Scottish Gynaecological Cancer Study Group
Bevacizumab Specialized pathology review E182 (Germany only) 800 AGO Study Group; ARCAGY/GINECO GROUP; Nordic Society for Gynaecologic Oncology
N/A N/A 223 Amgen
N/A Behavioral dietary intervention; compliance monitoring; counseling; educational intervention; exercise intervention; LBA; QOL assessment; questionnaire administration 1,070 Gynecologic Oncology Group; NCI
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
NCT Number Title Drug Intervention
NCT01628380* Phase 3 Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy in Upfront Treatment of Stage IIIC Epithelial Ovarian Cancer N/A
NCT00426257* Secondary Debulking Surgery +/–Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer N/A
NCT01802749* Bevacizumab Beyond Progression in Platinum-Sensitive Ovarian Cancer Bevacizumab; paclitaxel; carboplatin; pegylated liposomal doxorubicin; gemcitabine
NCT01654146* ICON8: Weekly Chemotherapy in Ovarian Cancer Carboplatin; paclitaxel
NCT01846611* A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Trabectedin; DOXIL; dexamethasone
NCT00565851* Carboplatin, Paclitaxel, and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Carboplatin; docetaxel; gemcitabine hydrochloride; paclitaxel
NCT01611766* Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)? Salvage chemotherapy
NCT01376752* Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment N/A
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Biological Intervention Other Intervention Estimated Enrollment Sponsor/Collaborators
N/A Cytoreductive surgery and HIPEC; cytoreductive surgery alone 94 A.O. Ospedale Papa Giovanni XXIII; Clinical Organization for Strategies & Solutions (CLIOSS), former Nerviano Medical Sciences; Onlus Cancro Primo Aiuto
N/A Secondary debulking with or without IP chemotherapy 280 The Netherlands Cancer Institute
N/A N/A 400 National Cancer Institute, Naples; Mario Negri Institute for Pharmacological Research
N/A N/A 1,485 Medical Research Council; Cancer Research UK
N/A N/A 670 Janssen Research & Development, LLC; PharmaMar
Bevacizumab LBA; QOL assessment 1,038 NCI
N/A Secondary cytoreductive surgery 420 Shanghai Gynecologic Oncology Group; Fudan University; Zhejiang Cancer Hospital; Shanghai Zhongshan Hospital; Sun Yat-sen University
N/A Maximal cytoreductive surgery 444 UNICANCER
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
NCT Number Title Drug Intervention
NCT02446600* Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Carboplatin; cediranib maleate; gemcitabine hydrochloride; olaparib; paclitaxel; pegylated liposomal doxorubicin hydrochloride
Phase IV Interventional Studies
NCT01706120 Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin + Paclitaxel With Bevacizumab Bevacizumab; paclitaxel; carboplatin
Interventional Studies (Phase Not Indicated)
NCT01747798 Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Auranofin
NCT02096783 Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer N/A
NCT01696994 Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial) N/A
NCT02595281 HE4 as a Relapse Biomarker in Ovarian Cancers N/A
NCT00946283 Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome N/A
NCT02578888* Palliative Care in Improving QOL in Patients With High-Risk Primary or Recurrent Gynecologic Malignancies N/A
NCT02013492* Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed by Surgery Propranolol hydrochloride
NCT01442051* Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer N/A
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Biological Intervention Other Intervention Estimated Enrollment Sponsor/Collaborators
N/A LBA; QOL assessment 450 NCI
N/A N/A 400 National Cancer Institute, Naples; Mario Negri Institute for Pharmacological Research
N/A LBA 10 Mayo Clinic
N/A Informational intervention; counseling intervention; questionnaire administration 30 University of Wisconsin–Madison; NCI
N/A Ultrasound imaging; screening questionnaire administration; LBA 78,216 NCI
N/A Experimental arm 90 Institut de Cancérologie de Lorraine
N/A Lactobacillus rhamnosus GG (dietary supplement) 30 Rutgers, The State University of New Jersey; NCI; Rutgers Cancer Institute of New Jersey
N/A Palliative therapy; palliative therapy + idiographic 180 Albert Einstein College of Medicine of Yeshiva University; NCI
N/A Correlative studies 35 William Carson; Ohio State University Comprehensive Cancer Center
N/A Acute normovolemic hemodilution 41 Memorial Sloan Kettering Cancer Center
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
NCT Number Title Drug Intervention
NCT02530606* Photoacoustic Imaging in Detecting Ovarian or Fallopian Tube Cancer N/A
NCT02412124* Peer-to-Peer Support Program in Improving QOL Outcomes in Patients With Gynecologic Cancer and Their Caregivers N/A
NCT02218502* Study Into a New Diagnostic Tool (Simple Ultrasound-based Rules) in Patients With Adnexal Masses N/A
NCT01519869* Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma Neoadjuvant chemotherapy
NCT02477202* Mirena® Intra-Uterine Device’s (IUD’s) Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation N/A
NCT01230346* Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer N/A
NCT02281487* Hysterectomy for Benign Gynaecological Conditions With or Without Tubectomy N/A
NCT01504126* Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients Propranolol; chemotherapy
NCT02530606* Photoacoustic Imaging in Detecting Ovarian or Fallopian Tube Cancer N/A
NCT02110277* Photoacoustic Imaging of the Ovary N/A
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Biological Intervention Other Intervention Estimated Enrollment Sponsor/Collaborators
N/A Photoacoustic imaging 20 Stanford University; NCI
N/A Supportive care; QOL assessment; questionnaire administration 30 City of Hope Medical Center; NCI
N/A Ultrasound by general gynaecologist; ultrasound by an expert ultrasonographist; DW-MRI; give blood sample 270 Maastricht University Medical Center; Laurentius Hospital Roermond; St. Jans Gasthuis Weert; VieCuri Medical Centre; Orbis Medical Centre
N/A N/A 28 Rachel Miller; University of Kentucky
N/A Mirena® IUD 14 Memorial Sloan Kettering Cancer Center
N/A Questionnaire administration; survey administration; counseling intervention; educational intervention 475 City of Hope Medical Center; NCI
N/A Hysterectomy with or without tubectomy; light microscopy 100 Gynaecologisch Oncologisch Centrum Zuid; St. Elisabeth Hospital, Tilburg, Netherlands; Catharina Ziekenhuis Eindhoven; Radboud University; Jeroen Bosch Ziekenhuis
N/A Surgery; questionnaire 25 MD Anderson Cancer Center; Sprint for Life
N/A Photoacoustic imaging 20 Stanford University; NCI
N/A Photoacoustic imaging/ultrasound diagnostic group (device) 40 University of Connecticut Health Center; NCI
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
NCT Number Title Drug Intervention
NCT01846520* Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II–IV Gastrointestinal, Gynecologic, and Urologic Cancers N/A
NCT02082470* Survivorship Care Planning in Improving QOL in Survivors of Ovarian Cancer N/A
NCT02323568* Live After an Epithelial Ovarian Cancer: Multidisciplinary Assessment of Effects and Long-term Remission in Patients Needs N/A
NCT02111941* Vaccine Therapy in Treating Patients With Stage IIIC–IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy N/A
NCT02039388* Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma N/A
NCT02376231* To Evaluate Plasmajet in Achieving Complete Cytoreduction of Advanced EOC–Initial Feasibility Study N/A
NCT02518256* Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma–Study of Sensitivity and Specificity N/A
NCT02062697* Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma and Their Premalignant Changes N/A
Observational Studies
NCT01276574 Epithelial Ovarian Cancer–Staging and Response to Chemotherapy Evaluated by PET/CT Not indicated
NCT00899093 Tumor Marker YKL-40 in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy N/A
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Biological Intervention Other Intervention Estimated Enrollment Sponsor/Collaborators
N/A Educational intervention; telephone-based intervention; QOL assessment; questionnaire administration 200 City of Hope Medical Center; NCI; American Cancer Society National Office
N/A Follow-up care; active surveillance; questionnaire administration 20 City of Hope Medical Center; NCI
N/A Gynecological consultation 120 Centre Francois Baclesse; Ligue contre le cancer, France; Fondation de France
Multi-epitope folate receptor alpha-loaded dendritic cell vaccine LBA 22 Mayo Clinic; NCI
N/A Lavage of the cavum uteri and proximal fallopian tubes 200 Medical University of Vienna
N/A Surgery for EOC with trial (PJ) device (PlasmaJet) 150 Thumuluru Kavitha Madhuri; Royal Surrey County Hospital; NHS Foundation Trust
N/A 540 Medical University of Vienna
N/A Lavage of the cavum uteri and proximal fallopian tubes; liquid-PAP smear 50 Medical University of Vienna
Not indicated Not indicated 150 Turku University Hospital
N/A LBA 2,500 Gynecologic Oncology Group; NCI
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
NCT Number Title Drug Intervention
NCT01080521 Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy N/A
NCT01295489 Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer IP chemotherapy
NCT00337233 Yoga in Controlling Symptoms and Reducing Stress in Women With Ovarian Cancer or Breast Cancer N/A
NCT00651716 T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant N/A
NCT00899496 Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants N/A
NCT02297958* Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma Not indicated
NCT02524808* Prospective Identification and Validation of “BRCANess” Profile in Ovarian Epithelial Cancer Not indicated
NCT00488878* Data Collection for Patients With Low-Grade Ovarian Carcinoma N/A
NCT01907789* Prophylactic Salpingectomy With Delayed Oophorectomy N/A
NCT01000259* Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer N/A
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Biological Intervention Other Intervention Estimated Enrollment Sponsor/Collaborators
N/A Cognitive assessment; QOL assessment 256 Gynecologic Oncology Group; NCI
N/A Gene expression analysis; protein analysis; flow cytometry; immunoenzyme technique; immunohistochemistry staining method; LBA 39 Gynecologic Oncology Group; NCI
N/A Yoga therapy 106 Comprehensive Cancer Center of Wake Forest University; NCI
N/A Flow cytometry; LBA; data collection 200 Vanderbilt-Ingram Cancer Center; NCI; NIH
N/A Immunological diagnostic method; physiologic testing 48 Comprehensive Cancer Center of Wake Forest University; NCI
Not Indicated Not indicated 40 Rennes University Hospital
Not Indicated Not indicated 230 Fundación de investigación HM; AstraZeneca
N/A Data collection 2,000 MD Anderson Cancer Center
N/A Ovarian cancer screening; prophylactic salpingectomy with delayed oophorectomy; risk-reducing salpingooophorectomy; questionnaire; transvaginal ultrasound; phone call 80 MD Anderson Cancer Center
N/A LBA 174 Gynecologic Oncology Group; NCI
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
NCT Number Title Drug Intervention
NCT00628654* Glycan Analysis in Diagnosing Cancer in Women With Ovarian Epithelial Cancer and in Healthy Female Participants Not indicated
NCT02315469* Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery N/A
NCT01832415* First-Line Ovarian Cancer Treatment–Cohort Study Bevacizumab
NCT02394015* Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC Trabectedin and pegylated liposomal doxorubicin
NCT01445275* Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 N/A
NCT02073500* Peritoneal Surface Malignancies–Characterization, Models and Treatment Strategies N/A
NCT02489058* A Study of Long-Term Responders on Olaparib Not indicated
NCT02291276* Perioperative Assessment of Right Ventricular Function and Venous Return in Patients With Epithelial Ovarian Cancer Undergoing Cytoreductive Surgery (Gyn Right)–Pilot Study Not indicated
NCT01932125* An Observational Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Not indicated
NCT02408536* Observational Retrospective Study on Treatment and Outcomes in Patients With Low-Grade Serous Ovarian Cancer Not indicated
NCT01703442* Intraoperative Anuric Episodes in Patients Undergoing Laparotomy Not indicated
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Biological Intervention Other Intervention Estimated Enrollment Sponsor/Collaborators
Not indicated Not indicated 700 University of California, Davis; NCI
N/A Comprehensive geriatric assessment; questionnaire administration 228 NRG Oncology; NCI
N/A N/A 500 ARCAGY/GINECO GROUP; Roche Pharma AG
N/A N/A 80 Grupo Español de Investigación en Cáncer de Ovario; PharmaMar
N/A Evaluation of cancer risk factors; medical chart review; study of socioeconomic and demographic variables 2,605 Gynecologic Oncology Group; NCI
N/A Observational study 200 Oslo University Hospital; The Research Council of Norway
Not indicated Not indicated 100 University Health Network, Toronto
Not indicated Not indicated 30 Charite University, Berlin, Germany
Not indicated Not indicated 100 Hoffmann-La Roche
Not indicated Not indicated 150 National Cancer Institute, Naples
Not indicated Not indicated 25 Claudia Spies; Charite University, Berlin, Germany
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
NCT Number Title Drug Intervention
NCT01982500* Observation of Bevacizumab Plus Front-Line Chemotherapy in Patients With Ovarian Cancer Not indicated
NCT00005095* Specimen and Data Study for Ovarian Cancer Early Detection and Prevention N/A
NCT02524808* Prospective Identification and Validation of “BRCANess” Profile in Ovarian Epithelial Cancer Not indicated
NCT02489058* A Study of Long-Term Responders on Olaparib Not indicated
NCT01703442* Intraoperative Anuric Episodes in Patients Undergoing Laparotomy Not indicated
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Biological Intervention Other Intervention Estimated Enrollment Sponsor/Collaborators
Not indicated Not indicated 200 Hellenic Oncology Research Group
N/A LBA; screening questionnaire administration; study of high-risk factors 6000 Northwestern University; NCI
Not indicated Not indicated 230 Fundación de investigación HM; AstraZeneca
Not indicated Not indicated 100 University Health Network, Toronto
Not indicated Not indicated 25 Claudia Spies; Charite University, Berlin, Germany
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×

This page intentionally left blank.

Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 313
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 314
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 315
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 316
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 317
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 318
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 319
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 320
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 321
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 322
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 323
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 324
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 325
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 326
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 327
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 328
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 329
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 330
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 331
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 332
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 333
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 334
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 335
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 336
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 337
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 338
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 339
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 340
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 341
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 342
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 343
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 344
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 345
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 346
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 347
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 348
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 349
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 350
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 351
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 352
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 353
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 354
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 355
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 356
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 357
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 358
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 359
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 360
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 361
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Page 362
Next: Appendix D: Workshop Agendas »
Ovarian Cancers: Evolving Paradigms in Research and Care Get This Book
×
Buy Paperback | $75.00 Buy Ebook | $59.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

In an era of promising advances in cancer research, there are considerable and even alarming gaps in the fundamental knowledge and understanding of ovarian cancer. Researchers now know that ovarian cancer is not a single disease--several distinct subtypes exist with different origins, risk factors, genetic mutations, biological behaviors, and prognoses. However, persistent questions have impeded progress toward improving the prevention, early detection, treatment, and management of ovarian cancers. Failure to significantly improve morbidity and mortality during the past several decades is likely due to several factors, including the lack of research being performed by specific disease subtype, lack of definitive knowledge of the cell of origin and disease progression, and incomplete understanding of genetic and non-genetic risk factors.

Ovarian Cancers examines the state of the science in ovarian cancer research, identifies key gaps in the evidence base and the challenges to addressing those gaps, considers opportunities for advancing ovarian cancer research, and examines avenues for translation and dissemination of new findings and communication of new information to patients and others. This study makes recommendations for public- and private-sector efforts that could facilitate progress in reducing the incidence of morbidity and mortality from ovarian cancers.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!